Cellevate AB and InVitria Inc. enter strategic collaboration to advance upstream bioprocessing solutions
Cellevate AB and InVitria Inc. enter strategic collaboration to advance upstream bioprocessing solutions for viral vaccine production
LUND, Sweden – March 10, 2026 – Cellevate AB today announces a strategic collaboration agreement with InVitria, Inc., a U.S.-based leader in chemically defined, animal-component-free cell culture media and recombinant protein solutions.
The collaboration will execute a joint development program integrating InVitria’s high-performance media with Cellevate’s Cellevat3d® nanofiber microcarrier platform. The program includes microcarrier screening, process optimization, virus production studies, and scale-up activities aimed at generating performance data to support future commercial deployment in viral vaccine manufacturing.
This partnership represents an important step in validating Cellevate’s technology within an integrated upstream workflow alongside a recognized U.S. media provider. By combining advanced nanofiber-based cell culture workflows with chemically defined media, the companies aim to deliver improved viral titers, enhanced scalability, reduced resource consumption, and significantly improved productivity at lower costs — key drivers for industrial vaccine production.
“This collaboration strengthens the commercial positioning of our Cellevat3d® platform by integrating it with complementary, industry-proven media solutions,” said Laura Chirica, CEO of Cellevate. “Generating industrially relevant performance data together with InVitria is an important milestone as we advance toward broader adoption and scale-up within vaccine manufacturing.”
“We are excited to collaborate with Cellevate to combine the potential of advanced nanofiber technology and chemically defined media. This partnership reflects our commitment to enabling more efficient and sustainable viral vaccine manufacturing processes,” said Scott Deeter, CEO, InVitria, Inc.
The results of the joint development program are expected to support future customer engagements and commercialization initiatives.
For more information, please contact:
Laura Chirica, PhD
CEO Cellevate
Email: laura.chirica@cellevate.com
About Cellevate
Cellevate is a Swedish biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture solutions for cell and gene therapy and novel vaccines biomanufacturing. The company is ISO 9001:2015 certified and has implemented GMP processes for production in clean room. The core nanotechnology, Cellevat3d® is a sustainable, deeptech innovation for the biopharmaceutical industry. This platform allows industrial-scale production of a new category of nanofiber cell culture systems – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to increased yield, productivity and process economy. Cellevat3d® nanofiber-based products are designed and validated as an integrated part of upstream bioprocessing solutions, from laboratory to large-scale production.
For more information, please visit www.cellevate.com.
About InVitria
InVitria is a global leader in the development and manufacture of high-performance blood-free cell culture and recombinant protein products designed to improve biomanufacturing and facilitate faster approval of life-changing therapies. The company provides unparalleled high-performance solutions for elimination of human and animal serum-derived raw materials in clinical manufacturing and commercial production of cell and gene therapies, vaccines, regenerative medicine, and medical devices. InVitria adheres to the FDA, and EMA regulations and offers cGMP and ISO compliant manufacturing capabilities scaled to meet growing global demand for chemically defined production of biologics.
For more information, please visit www.invitria.com.